Key Role of the GITR/GITRLigand Pathway in the Development of Murine Autoimmune Diabetes: A Potential Therapeutic Target

Sylvaine You1,2*, Lynn Poulton2, Steve Cobbold3, Chih-Pin Liu4, Michael Rosenzweig5, Douglas Ringler5, Wen-Hui Lee4, Berta Segovia1,2, Jean-François Bach1,2, Herman Waldmann3, Lucienne Chatenoud1,2

1 Université Paris Descartes, Paris, France, 2INSERM, Unité 580, Paris, France, 3University of Oxford, Sir William Dunn School of Pathology, Oxford, United Kingdom, 4Department of Immunology, Department of Diabetes, Endocrinology and Metabolism, Beckman Research Institute, City of Hope, Duarte, California, United States of America, 5Tolerx, Inc., Cambridge, Massachusetts, United States of America

Abstract

Background: The cross-talk between pathogenic T lymphocytes and regulatory T cells (Tregs) plays a major role in the progression of autoimmune diseases. Our objective is to identify molecules and/or pathways involved in this interaction and representing potential targets for innovative therapies. Glucocorticoid-induced tumor necrosis factor receptor (GITR) and its ligand are key players in the T effector/Treg interaction. GITR is expressed at low levels on resting T cells and is significantly up-regulated upon activation. Constitutive high expression of GITR is detected only on Tregs. GITR interacts with its ligand mainly expressed on antigen presenting cells and endothelial cells. It has been suggested that GITR triggering activates effector T lymphocytes while inhibiting Tregs thus contributing to the amplification of immune responses. In this study, we examined the role of GITR/GITRLigand interaction in the progression of autoimmune diabetes.

Methods and Findings: Treatment of 10-day-old non-obese diabetic (NOD) mice, which spontaneously develop diabetes, with an agonistic GITR-specific antibody induced a significant acceleration of disease onset (80% at 12 weeks of age). This activity was not due to a decline in the numbers or functional capacity of CD4+CD25+Foxp3+ Tregs but rather to a major activation of ‘diabetogenic’ T cells. This conclusion was supported by results showing that anti-GITR antibody exacerbates diabetes also in CD28+ BDC2.5 T cell clone, with GITR-specific antibody substantially increased their migration, proliferation and activation within the pancreatic islets and draining lymph nodes. As a mirror image, blockade of the GITR/GITRLigand pathway using a neutralizing GITRLigand-specific antibody significantly protected from diabetes even at late stages of disease progression. Experiments using the BDC2.5 T cell transfer model suggested that the GITRLigand antibody acted by limiting the homing and proliferation of pathogenic T cells in pancreatic lymph nodes.

Conclusion: GITR triggering plays an important costimulatory role on diabetogenic T cells contributing to the development of autoimmune responses. Therefore, blockade of the GITR/GITRLigand pathway appears as a novel promising clinically oriented strategy as GITRLigand-specific antibody applied at an advanced stage of disease progression can prevent overt diabetes.

Citation: You S, Poulton L, Cobbold S, Liu C-P, Rosenzweig M, et al. (2009) Key Role of the GITR/GITRLigand Pathway in the Development of Murine Autoimmune Diabetes: A Potential Therapeutic Target. PLoS ONE 4(11): e7848. doi:10.1371/journal.pone.0007848

Editor: Derya Unutmaz, New York University School of Medicine, United States of America

Received September 3, 2009; Accepted October 13, 2009; Published November 20, 2009

Copyright: © 2009 You et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by grants from INSERM, the Centaure Foundation and Fondation Day Solvay. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The participation as co-authors of Michael Rosenzweig and Douglas Ringer, who are employed by ToleRx, does not alter their adherence to all the PLoS ONE policies on sharing data and materials.

* E-mail: sylvaine.you@inserm.fr
distinct MAPKs pathways (ERKs, JNKs and p38) and activating NF-kB [6,10,11].

In the mouse, the ligand of GITR (GITRL) is expressed on endothelial cells and antigen presenting cells (APCs) including dendritic cells (DCs), macrophages and B cells [5,6,12]. Its expression is up-modulated by various pro-inflammatory stimuli [5,6]. At variance, in the human a more restricted distribution was described. Besides endothelial cells, human GITRL is exclusively detected on activated plasmacytoid DCs but not on T cells, B cells, NK cells, macrophages, mature or immature myeloid DCs [13,14]. In addition, over expression of GITRL in human monocyte-derived DCs enhances their capacity to activate T cells by providing costimulatory signals [14]. In macrophages, GITRL signaling leads to the production of pro-inflammatory mediators such as IL-1β, IL-8, TNF-α, MCP-1, inducible nitric oxide synthetase (iNOS) and matrix metalloproteinase (MMP)-9 [15,16]. Interestingly, a recent report showed that, in mouse, plasmacytoid DCs reverse signaling through GITRL could also activate indoleamine 2,3-dioxigenase (IDO) thus inducing a major down-regulatory loop through the tryptophan catabolism regulatory pathway [17].

Compelling evidence has accumulated to show that in vivo triggering of GITR with an agonistic monoclonal antibody significantly up-regulates immune responses to tumors and infectious agents thus facilitating their eradication, and so representing a suitable ‘adjuvant’ strategy in these situations [18–22]. In keeping with these observations are data showing that treatment with anti-GITR also exacerbates the development of autoimmune and allergic disorders including autoimmune gastritis [1], experimental autoimmune encephalomyelitis (EAE) [23], experimental collagen-induced arthritis (CIA) and asthma [24]. As a mirror image of these findings, GITR-deficient mice (GITR−/−) show significantly reduced inflammatory reactions as compared to wild-type animals in response to various stimuli i.e. chronic lung injury induced by bleomycin instillation, type II collagen-induced arthritis, TNBS (2,4,6-trinitrobenzene sulphonic acid)-induced colitis [25–27]. In toto, these data strongly suggest that, if properly manipulated, the GITR/GITRL pathway could represent an interesting therapeutic target in quite distinct settings. As mentioned, GITR triggering is beneficial in the infectious and tumor setting. Conversely, in the particular case of autoimmunity, while GITR activation appears counterproductive, no reagents were available until recently to assess whether effective blockade of the GITR/GITRL interaction could inhibit lymphocyte autoreactivity and prevent autoimmunity.

In this study, we have examined, for the first time, the role of the GITR/GITRL pathway in the course of a spontaneous autoimmune disease, insulin-dependent type 1 diabetes, using the non-obese diabetic (NOD) mouse that in many aspects recapitulates the human disease [28]. Our data demonstrate, in keeping with previous reports in other autoimmune conditions, that GITR triggering exacerbates autoimmune diabetes. However, our results extend previous findings in showing that this accelerating effect is a consequence of selective activation/costimulation of pathogenic T cells while Tregs are spared. A second important and novel finding is that a blocking antibody to GITRL can effectively prevent the onset of diabetes.

Materials and Methods

Mice

NOD (Kd, I-Ak, Dk), BDC2.5 NOD, CD28−/− NOD (kindly provided by J. Bluestone, Diabetes Center and Department of Medicine, University of California, San Francisco) and NOD-SCID mice were bred in our animal facilities under specific pathogen-free conditions. Colorimetric strips were used to monitor glycemia (Glukotest, Boehringer-Mannheim, Mannheim, Germany) and fasting glycemia (Haemoglukotest and Reflolux F; Boehringer-Mannheim). Ethical statement: All experiments have been conducted in accordance with European Union Council Directives (86/609/ EEC) and with institutional guidelines (INSERM, Institut National de la Santé et de la Recherche Médicale). The animal facility has an agreement delivered by the Prefecture de Police de Paris, France.

Antibody Treatment

Ten day-old NOD or CD28−/− NOD mice were treated with anti-GITR antibody (rat IgG2a antibody 2F8) (Tolerx Inc., Cambridge, MA) or purified mouse IgGs (Jackson laboratories, West Grove, PA). The dose used was 0.2, 0.4 or 0.8 mg/injection i.p. on d10, d17 and d24 of life. Anti-GITRLigand antibody (rat IgG1 antibody YGL 386.2 [5]) was administered i.p. at the dose of 1 mg/injection. Eleven week-old NOD mice received 1 mg/week for 4 weeks. In another experiment, anti-GITL treatment was started at 6 weeks of age in CD28−/− NOD mice (week 6 to 9 included).

Histology

Stomach, pancreas, salivary glands and thyroid were fixed in 4% formalin and processed according to standard methods. Five μm thick paraffin sections stained with hematoxylin-eosin-safran were examined.

Adoptive Transfer

Total splenocytes were recovered from 32-week-old diabetes-free NOD mice that have been treated with anti-GITRL antibody (from week 11 to 14 of life). After depletion of B cells by magnetic bead cell sorting (Miltenyi Biotech), Tregs were removed on the basis of their expression of CD25 or CD62L. Purity of the sorted cells was 90–95%. CD25−CD62L− T cells were then injected i.v. into 6-week-old NOD-SCID mice (107/recipient) and diabetes was monitored 2 times a week until disease occurred.

Infusion of CFSE-Labeled BDC2.5 Cells

CD4+ T cells were purified from BDC2.5 NOD splenocytes [29] by magnetic cell sorting (Miltenyi Biotech, Germany). BDC2.5 T cells represent more than 80% of the CD4+ population [30]. The cells were labeled with carboxyfluorescein diacetate succinimidyl ester (CFSE, 1 μM, 10 min at 37°C) and transferred i.v. into 3 to 4-wk-old NOD mice (107/recipient). Recipient animals were treated either with anti-GITR (1 mg/injection) or with anti-GITRLigand antibodies (1 mg/injection) on day 0, 1 and 4 after BDC2.5 T cell infusion. Pancreas, spleen, pancreatic and mesenteric lymph nodes were harvested on day 7. Pancreatic islets were isolated by Histopaque gradient (Sigma, France) after collagenase P digestion (0.6 mg/ml, 15 min at 37°C) and infiltrating T cells were subsequently collected after islet trypsin/EDTA treatment.

Flow Cytometry

CD25, CD4, CD8, CD44 and CD69 antibodies were obtained from PharMingen-BD (San Diego, CA). The biotinylated anti-GITR antibody (clone YGITR 765.4, rat IgG2b) previously described [3,31] was used. Foxp3 intracellular staining was performed according to the manufacturer’s instructions (eBioscience, San Diego, CA). The class II MHC tetramer carrying a BDC2.5 T cell-specific minitope (tetAg7/p79) was
used as previously described [30]. Briefly, cells were stained with PE-labeled tetramers (5 µg/ml) at 37°C for 3 hrs. Cell surface antibodies were added during the last 30 min of incubation.

**In Vitro Proliferation Assays**

CD4+CD25- and CD4+CD25+ T cells (2×10^5 cells/well) were cultured at a 1:1 ratio and stimulated with CD3 antibody (2.5 µg/ml) and APCs. To assess GITR costimulatory function, CD4+CD25+ or CD4+CD25- T cells were stimulated with CD3 antibody (145 2C11, 0.5 µg/ml) and increasing concentrations of anti-GITR antibody. In other experiments, CD4+CD25+ T cells were first stimulated with CD3 antibody alone (0.5 µg/ml) or in combination with anti-GITR antibody (50 µg/ml) for 48 hrs and then co-cultured with freshly isolated CD4+CD25- T cells in the presence of APCs and CD3 antibody. In all settings, cells were incubated for 72 hrs and pulsed with [3H]-thymidine (Amersham). Data from the co-cultures were expressed as the % inhibition = [1−(cpm CD4+CD25− plus CD4+CD25+)/cpm CD4+CD25−)]×100.

**Elispot Assay**

PVDF plates (Millipore, St Quentin-en-Yvelines, France) were coated overnight with anti-IFN-γ antibody (U-Cytech, Utrecht, the Netherlands). CD4+CD25- or CD8+ T cells were added (1.5×10^5/well) and stimulated with CD3 antibody (0.05 µg/ml) and increasing concentrations of anti-GITR antibody for 20 hr. In additional experiments, CD4+CD25+ T cells were cultured with an agonist mimotope peptide (1040-51, 2 ng/ml). After cell removal, IFN-γ secretion was detected with biotinylated anti-IFN-γ antibody, streptavidin-horseradish peroxidase and 3-amino-9-ethylcarbazole (AEC). All IFN-γ spot readouts were expressed as spot-forming cells (SFC/10^6 cells.

**Statistical Analysis**

The occurrence of diabetes was plotted using the Kaplan-Meier method. The statistical comparison between the curves was performed using the logrank (Mantel-Cox) test. In addition, results were analyzed using the Student’s t test when appropriate.

**Results**

1) GITR Triggering Boosts Diabetogenic T Cells in NOD Mice both In Vivo and In Vitro

As already mentioned, in various models of autoimmunity (autoimmune gastritis, EAE, CIA), disease exacerbation has been reported following administration of an agonistic anti-GITR antibody, DTA-1, produced by the group of S. Sakaguchi [1].

Here, using another agonistic antibody, we studied the effect of GITR triggering in autoimmune insulin-dependent diabetes. To that aim, we used two different models, namely conventional NOD mice and BDC2.5 NOD mice that express a transgenic TCR derived from a pathogenic (‘diabetogenic’) CD4+ T cell clone [29].

a) Acceleration of insulitis and diabetes progression. Ten day-old female NOD mice were injected i.p. with increasing doses of a GITR-specific antibody, 2FB, (0.2, 0.4 or 0.8 mg/injection on day 10, 17 and 24 of life). The anti-GITR antibody used in our study, like the DTA-1 produced by the group of Sakaguchi [1], is agonistic. Control mice were treated with purified mouse IgGs. As shown in figure 1A, anti-GITR-treated mice showed a significant and quite impressive acceleration of overt diabetes onset; mice receiving the higher anti-GITR dose developed hyperglycemia and glycosuria by 6–8 weeks of age that is 5–7 weeks before disease onset in control NOD females. The effect was dose-dependent; at 12 weeks of age, diabetes was observed in 80%, 50% and 35% of NOD females treated with 0.8 mg, 0.4 mg or 0.2 mg of anti-GITR, respectively (figure 1A). Consistent with this marked acceleration of disease, histological examination of pancreata showed a significantly more rapid progression from benign to aggressive/destructive insulitis in anti-GITR-treated NOD mice as compared to controls (figure 1B). Thus, by 8 weeks of age, 82% of the islets were massively infiltrated as compared to 25% in control animals (figure 1B).

Anti-GITR-treated NOD mice were also examined for the occurrence of other autoimmune manifestations including sialitis, gastritis and thyroiditis (figure 1C). As compared to control mice, anti-GITR-treated NOD females exhibited more severe and rapidly progressing sialitis. Gastritis was also observed in 12% of the treated animals but remained modest. Finally, histological analysis did not reveal any sign of autoimmune thyroiditis (data not shown).

Major lymphocyte subsets were analyzed in the spleen of anti-GITR-treated and control animals. At 4 weeks of age (i.e. 2–3 days after the last injection), anti-GITR-treated mice exhibited significantly higher proportions of both CD4+ and CD8+ T cells as compared to IgG-treated controls (33.7% versus 13.4% for CD4+ and 12.2% versus 5.8% for CD8+) (figure 2A). The pattern was back to normal by 2 weeks after the end of treatment (figure 2A).

At early time points after anti-GITR treatment, clear phenotypic evidence of T cell activation was observed within the CD4+ compartment as assessed by an increase in CD69 and CD44 expressing cells and a decrease in CD62Lhigh expressing cells (data not shown). Moreover, in anti-GITR-treated NOD mice, very high proportions of CD4+CD25+ T cells expressed CD103 (>60% at 4 weeks of age) (figure 2B), an effect that progressively declined after the end of the treatment (45% and 35% of CD103+ were observed at 9 or 12 weeks of age, respectively).

As already reported in the literature, GITR is constitutively expressed by CD4+CD25+ Tregs. The proportion of CD4+CD25+ T cells was not affected by anti-GITR antibody treatment. In treated animals, GITR-expressing cells were coated by the in vivo-injected antibody, a phenomenon which, in mice receiving the highest dose, lasted 4–5 weeks after treatment (data not shown).

b) GITR ligation on effector T cells is costimulatory in vitro. To further investigate the costimulatory role of GITR on pathogenic/effector T cells, CD4+CD25− T cells from anti-GITR-treated or control NOD mice were purified and stimulated in vitro with increasing doses of CD3 antibody. Results showed that CD4+CD25+ T cells from anti-GITR antibody-treated NOD mice proliferated better even at the lowest dose of anti-CD3 (0.05 µg/ml: 29618 cpm as compared to 5050 cpm for controls; p<0.0001) thus confirming the increased activation pattern exhibited by CD4+ T cells following GITR triggering (figure 3A).

In another set of experiments, CD4+CD25− T cells from non-manipulated NOD mice cultured in presence of low concentrations of anti-CD3 showed a dose-dependent proliferative response following addition of increasing amounts of anti-GITR antibody (figure 3B). Moreover, using an ELISPOT assay, we measured IFN-γ production by CD4+CD25− or CD8+ T cells after a 20 hr stimulation in presence of sub-optimal concentrations of anti-CD3 and increasing doses of anti-GITR (figure 3C). The same experiment was performed using transgenic CD4+ T cells from non-manipulated NOD mice cultured in presence of low concentrations of anti-CD3 showing a dose-dependent proliferative response following addition of increasing amounts of anti-GITR antibody (figure 3B).

In both cases, addition of anti-GITR antibody resulted in a greater IFN-γ production in a dose-dependent fashion (figure 3C).

c) GITR triggering enhanced in vivo proliferation and migration of effector T cells to the pancreas. The diabetogenic CD4+ Th1 cell clone BDC2.5, from which the
transgenic TCR was isolated, is specific for a still non characterized beta-cell-specific autoantigen presented in the context of NOD (H2Kd) class II MHC molecules [32–34]. Transgenic BDC2.5 cells are highly pathogenic. When the transgene is expressed in the NOD-SCID or Rag2−/− NOD backgrounds, all T cells express the BDC2.5 TCR (since recombination of endogenous TCRα chains is prevented) resulting in a massive destructive infiltration of pancreatic islets (insulitis) and overt diabetes two to three weeks after birth [29,33,34]. As described by the group of D. Mathis, when adoptively transferred into intact NOD mice, transgenic BDC2.5 T cells rapidly migrate to the pancreatic lymph nodes where they actively proliferate before invading the islets [35]. We used this model to better assess the effect of anti-GITR on effector T cells in vivo. CFSE-labeled transgenic CD4+ BDC2.5 T cells were injected i.v. into 3-week-old NOD mice and their distribution and expansion was monitored in anti-GITR-treated and control recipients. Anti-GITR antibody was administered on day 0, 1 and 4 following BDC2.5 cell infusion; pancreatic lymph nodes as well as pancreatic islets were recovered on day 7. To specifically detect CD4+ BDC2.5 T cells, we used I-A g7 MHC class II tetramers (tetp79) presenting a synthetic peptide 1040-79 (p79) selectively recognized by the BDC2.5 clone [30,36]. The number of both CD4+ and CD8+ T cells accumulating within the islets was 3–4 fold higher in recipients treated with anti-GITR antibody as compared to controls (figure 4A, p<0.003). Interestingly, in the islet infiltrate, the proportion of CD8+ T cells increased from 18% to 31% while, in parallel, in pancreatic lymph nodes it decreased from 32% to 23% (figure 4B). The proportion of total CD4+ T cells remained unchanged in these two compartments (figure 4A and B). However, a significantly higher proportion of BDC2.5 T cells (stained by the Ag7/p79 tetramer) was observed in the islets, but not in pancreatic lymph nodes, of recipients treated with anti-GITR antibody as compared to controls (11.5% versus 1.3%, figure 4A, p<0.04). BDC2.5 T cells actively proliferated in pancreatic lymph nodes and in the islets of recipient mice. This proliferation was clearly enhanced following anti-GITR treatment; 84% of islet-infiltrating BDC2.5 T cells underwent more than 5 divisions (figure 4C). Similarly, only 21% of BDC2.5 T cells present in pancreatic lymph nodes of anti-GITR-treated animals were non-dividing as compared to 49% in the control mice. BDC2.5 T cells were mostly found in the close vicinity of the target organ. A minor proportion of them were detected in the spleen and the mesenteric lymph nodes of recipient mice; they did not proliferate and their frequency did not increase following anti-GITR treatment (data not shown).
Figure 3. GITR acts as a costimulatory molecule on T cells. (A) Proliferation of CD4+CD25− T cells issued from the spleen of 6-wk-old NOD mice injected with anti-GITR antibody (0.8 mg) or PBS (controls) on d10, d14 and d24 in response to increasing concentrations of anti-CD3 antibody. (B) CD25 staining in CD4 gate and CD103 staining in CD4+CD25− T cell gate.

doi:10.1371/journal.pone.0007848.g003
2) GITR Ligation Does Not Abrogate Treg Function

a) No effect of in vivo and in vitro anti-GITR treatment on Treg function. It has been suggested that ligation of GITR inhibits the suppressive capacity of Tregs [1,4,8,37]. We investigated the in vitro suppressive capacities of the CD4<sup>+</sup>CD25<sup>+</sup> T cells isolated from the spleen of GITR antibody-treated mice using the conventional non antigen-specific co-culture model. CD4<sup>+</sup>CD25<sup>+</sup> and CD4<sup>+</sup>CD25<sup>+</sup> T cells were recovered from NOD mice 2 weeks after the last anti-GITR injection. As shown on figure 5A, CD4<sup>+</sup>CD25<sup>+</sup> T cells from anti-GITR-treated NOD mice efficiently suppressed the proliferation of CD4<sup>+</sup>CD25<sup>+</sup> T cells recovered from the same donor. To further examine if GITR triggering altered the regulatory properties of the CD4<sup>+</sup>CD25<sup>+</sup> subset, we performed criss-cross co-cultures. CD4<sup>+</sup>CD25<sup>+</sup> T cells from anti-GITR-treated NOD mice suppressed proliferation of CD4<sup>+</sup>CD25<sup>+</sup> T cells from control mice as efficiently as Tregs from the same control mice (figure 5A). FoxP3 expression was investigated and was detected in the majority of the CD4<sup>+</sup>CD25<sup>+</sup> T cells both in anti-GITR-treated and in control animals (figure 5B).

Using another in vitro experimental design, we studied the effect of GITR triggering on TCR-stimulated CD4<sup>+</sup>CD25<sup>+</sup> T cells recovered from non-manipulated NOD mice. We showed that addition of increasing concentrations of the anti-GITR agonist antibody resulted in a dose-dependent enhancement of CD4<sup>+</sup>CD25<sup>+</sup> T cell proliferation (figure 5C) i.e. CD4<sup>+</sup>CD25<sup>+</sup> T cells lost their anergic state in response to CD3 antibody. However, these CD4<sup>+</sup>CD25<sup>+</sup> T cells that have been previously stimulated with a combination of CD3 and GITR antibodies exhibited suppressive capacities similar to the one afforded by freshly isolated CD4<sup>+</sup>CD25<sup>+</sup> T cells or CD4<sup>+</sup>CD25<sup>+</sup> T cells cultured with CD3 antibody alone (figure 5D).

b) The CD28<sup>−/−</sup> NOD mouse model. To further confirm that anti-GITR treatment selectively acted on effector T cells but spared Tregs, we used NOD mice deficient in the cd28 encoding gene (CD28<sup>−/−</sup> NOD). These mice are deprived of natural CD25<sup>+</sup>FoxP3<sup>+</sup> natural Tregs and they exhibit exacerbated Th1 responses and accelerated diabetes [38,39]. Anti-GITR antibody treatment was performed in 10 day-old female CD28<sup>−/−</sup> NOD mice (0.8 mg/injection on d10, d17 and d24 of life). As expected, 66.7% of control animals that received control IgGs showed overt disease by 15 weeks of age (figure 6A). Anti-GITR-treated mice showed acceleration of disease onset reaching 100% of diabetes

Figure 4. In vivo GITR costimulatory action on BDC2.5 T cells. Three to four-week-old NOD mice were infused with 10<sup>7</sup> CFSE-labeled CD4<sup>+</sup>BDC2.5 T cells and were treated or not with anti-GITR antibody on day 0, 1 and day 4 after transfer. Recipient mice were sacrificed on day 7 and cell suspensions were recovered from the pancreatic islets and lymph nodes and analyzed by flow cytometry. (A) FACS analysis in the pancreatic islets. Upper panel: proportion of CD4<sup>+</sup> and CD8<sup>+</sup> T cells detected within the islets; lower panel: tet/p79 tetramer staining (MHC class II tetramer carrying a BDC2.5 T cell-specific peptide p79) in the CD4<sup>+</sup> T cell gate (p<0.04). Histogram: islet infiltrating CD4<sup>+</sup> and CD8<sup>+</sup> T cell count (*p<0.003). (B) FACS analysis in the pancreatic lymph nodes (PLN). Upper panel: distribution of CD4<sup>+</sup> and CD8<sup>+</sup> T cells, lower panel: tet/p79 tetramer staining in the CD4<sup>+</sup> T cell gate. (C) Proliferation of BDC2.5 T cells in the pancreatic lymph nodes (PLN) and islets of recipient NOD mice measured by CFSE staining in the CD4<sup>+</sup>Tet/p79<sup>+</sup> T cell gate. The results shown here are representative of three independent experiments.

doi:10.1371/journal.pone.0007848.g004
incidence by 9 weeks of age. Histological examination of pancreata recovered from 9-week-old anti-GITR antibody-treated CD28−/− NOD mice showed more than 95% of massively infiltrated and destroyed islets (as compared to 43% in the control group) (figure 6B).

3) Blockade of GITR Ligand Is Effective at Preventing Disease Progression

a) Treatment of NOD mice with a short anti-GITRL course protects from diabetes. As a whole, the data presented above clearly suggest that GITR triggering promotes exacerbation of autoimmune diabetes consequent to the activation of diabetogenic T cells without significantly affecting the Treg pool. We therefore hypothesized that blocking GITR/GITRL interaction may represent a promising therapeutic strategy to control diabetes development.

To directly test this hypothesis, a monoclonal anti-GITRL antibody (clone YGL 386.2), that interferes with the GITR/GITRL interaction, was injected intraperitoneally (1 mg/injection/week) at a late pre-diabetic stage (11-week-old) for only 4 consecutive weeks. Diabetes incidence was significantly reduced: 0% versus 78% diabetes in the control group at 20 weeks of age, 16.6% versus 100% at 25 weeks of age and 33% versus 100% diabetes at 30 weeks of age (figure 7A). Phenotypic analysis of various lymphoid organs (spleen, mesenteric, pancreatic lymph nodes) did not reveal any major modification of the T cell compartment as compared to untreated NOD mice (data not shown). In particular, the proportion and the suppressive functions of CD4+CD25+FoxP3+ regulatory T cells recovered from anti-GITRL antibody-treated NOD mice at different time points following treatment were not modified as compared to age-matched controls (data not shown).

b) Anti-GITRL antibody-protected NOD mice harbor pathogenic T cells. We next tested whether protected NOD mice still harbored pathogenic T cells. Total splenocytes were harvested from 32-week-old anti-GITRL antibody-treated diabetes-free NOD mice and were depleted of regulatory T cells i.e. CD4+CD25+ T cells and CD4+CD62L− T cells [39–41]. The CD25−CD62L− T cell fraction, that included diabetogenic effectors [42], was adoptively transferred into 6-week-old NOD-SCID mice (106/recipient). As shown on figure 7B, CD25−CD62L− T cells from anti-GITRL-treated donors were still able to transfer disease as efficiently as T cells from overtly diabetic NOD mice. This result argues against the deletion
of diabetogenic T cells following the anti-GITRL antibody treatment.

4) Blockade of the GITR/GITRL Pathway Reduced In Vivo Proliferation and Migration of Effector T Cells to the Pancreas

The data presented above indirectly suggest a critical role for the GITR/GITRL interaction in the migration of pathogenic effector T cells to the target tissue. To assess more directly whether blockade of the GITR/GITRL pathway directly interfered with the activation and/or migration of effector T cell reactivity, we took advantage of the experimental design described above using CFSE-labeled CD4\(^+\) BDC2.5 T cells. BDC2.5 T cells were infused into 4-week-old NOD mice that were then treated with 1 mg anti-GITRL antibody on day 0, 1 and day 4. Spleen, mesenteric and pancreatic lymph nodes as well as pancreatic islets were recovered on day 7.

The analysis of immune cells infiltrating the pancreatic islets showed that less CD4\(^+\) T cells were detected after injection of anti-GITRL antibody (17.9% versus 24.8% in islets from untreated animals) (figure 8A, p<0.007). Among these CD4\(^+\) T cells, 13.1% were stained with tetr79 as compared to 18.2% in controls (figure 8B, p<0.01). In other words, proliferating BDC2.5 T cells represent 2.3% of the total lymphocytes found within the pancreatic islets of anti-GITRL-treated recipient mice as compared to 4.5% in untreated animals (data not shown). Interestingly, the proportion of CD8\(^+\) T cells present within the islets was decreased after anti-GITRL antibody treatment as compared to untreated recipient NOD mice (figure 8A, p<0.02).

BDC2.5 T cells accumulated less (3.3% of total CD4\(^+\) Tc e l l s versus 5.1% in untreated animals, figure 8B, p<0.05) and, importantly, proliferated less in pancreatic lymph nodes of NOD mice treated with anti-GITRL antibody (Figure 8C). Only 22% of the BDC2.5 T cells underwent at least one division after administration of anti-GITRL antibody as compared to 34.5% without treatment (figure 8C). Phenotypic analysis was performed on the BDC2.5 T cells infused into NOD mice treated or not with anti-GITRL antibody. Expression of CD44\(^{hi}\) was clearly detected on T cells that proliferated in the pancreatic lymph nodes of recipient mice (figure 9A). However, correlating with the previous results (figure 8B), less BDC2.5 T cells were CFSE\(^{lo}\)/CD44\(^{hi}\) after administration of anti-GITRL antibody (figure 9A, p<0.05). Similarly, BDC2.5 T cells that migrated to the pancreatic lymph nodes of anti-GITRL antibody-treated mice expressed lower levels of CD69 (figure 9B). Interestingly, we observed that CD69 staining intensity decreased as
cells divided. In control animals, BDC2.5 T cells (13.6%) that underwent several rounds of cell division did not express CD69 (figure 9B). This CFSE\textsuperscript{low}CD69\textsuperscript{2} population is present at a lower proportion in anti-GITRL antibody-treated mice (p = 0.04). CD69 is an early activation marker. The lack of expression of CD69 on a fraction of proliferating CFSE\textsuperscript{low} T cells, as well as their high expression of CD44, suggest that, in untreated NOD mice, BDC2.5 T cells have already gone through several rounds of activation and exhibit an effector/memory-like phenotype. This is not the case in anti-GITRL antibody-treated mice.

Some BDC2.5 T cells did proliferate and acquired the activation markers CD44\textsuperscript{high} and CD69 in the mesenteric lymph nodes of anti-GITRL antibody-treated mice (figure 9A and B). In contrast, BDC2.5 T cells detected in the spleen of recipient NOD mice (around 3% of total T cells) did not proliferate nor express CD44\textsuperscript{high} or CD69, independently of any antibody treatment (data not shown).

5) The Protective Effect of Anti-GITRL Is Independent of the Presence of Treg

To further investigate the effect of blocking GITR/GITRL pathway on effector T cell functions, pre-diabetic 6-week-old CD28\textsuperscript{−/−} NOD mice were treated with an anti-GITRL antibody (1 mg/injection on week 6 to 9). Administration of this anti-GITRL antibody significantly delayed (but did not abrogate) diabetes development in CD28\textsuperscript{−/−} NOD mice (figure 10), as opposed to what observed with the agonist anti-GITR antibody (figure 6A).

Discussion

Type 1 diabetes is a prototypic organ-specific autoimmune disease resulting from the selective destruction of insulin-secreting beta-cells within pancreatic islets of Langerhans by an immune-mediated inflammation involving autoreactive CD4\textsuperscript{+} and CD8\textsuperscript{+} T lymphocytes and monocytic cells which infiltrate pancreatic islets (insulitis) [43]. Current treatment is substitutive i.e. chronic use of exogenous insulin which is, in spite of significant advances, still associated with major constraints (multiple daily injections, risks of hypoglycemia) and a lack of effectiveness over the long term in preventing severe degenerative complications. Finding a cure for autoimmune diabetes is a real health challenge since its incidence steadily increases in industrialized countries [44,45]. Our present results demonstrate a key role of the GITR/GITRL pathway in
the progression of autoimmune diabetes and point to its potential as a therapeutic target. On one hand, GITR triggering following \textit{in vivo} administration of an agonistic anti-GITR monoclonal antibody promotes a clear-cut exacerbation of disease. On the other hand, adequate pharmacological blockade of this pathway following short-term \textit{in vivo} treatment with an anti-GITRL antibody is effective at protecting from disease development. For the sake of clarity, we shall discuss these two aspects of our work consecutively.

The capacity to significantly up-regulate immune responses upon GITR triggering is quite remarkable and covers the whole spectrum of antigens that have been studied, including infectious and tumor antigens, autoantigens and alloantigens. This effect was initially described by the group of S. Sakaguchi in autoimmunity with the DTA-1 antibody (a rat anti-mouse GITR monoclonal) they had produced using natural CD4$^+$CD25$^+$Tregs as an immunogen \cite{1}. The DTA-1 antibody blocked the \textit{in vitro} suppressive ability of CD4$^+$CD25$^+$T cells. Additional experiments confirmed the agonistic properties of DTA-1 through active GITR signaling and not mere blockade of the receptor; only the intact antibody but not Fab fragments mediated the effect \cite{1}. \textit{In vivo}, only 3 injections of the anti-GITR antibody (once a week for 3 weeks) to very young BALB/c mice (2 week-old) induced by 3 months of age histological and serological evidence of autoimmune gastritis \cite{1}, a situation partly resembling that induced following elimination of CD4$^+$CD25$^+$T cells by day 3 thymectomy in BALB/c mice \cite{46}. In EAE, the same anti-GITR antibody significantly increased disease severity and CNS inflammation and induced elevated levels of antigen-specific T cell proliferation and cytokine production \cite{23}. Similarly, both Th1- and Th2-mediated inflammatory disorders (collagen-induced arthritis and asthma, respectively) were exacerbated after injection of anti-GITR \cite{24}.

In the present report, we extended these data to a spontaneous autoimmune insulin-dependent diabetes model, the NOD mouse, that recapitulates many aspects of the human disease. Using another agonistic anti-GITR antibody, 2F8, we found a very significant acceleration of disease onset following a short treatment course (3 injections, once a week) started in young mice (10 days of age). As in the case of DTA-1, our 2F8 antibody did not eliminate GITR-expressing cells. Histological autoimmune sialitis, that is spontaneously observed in NOD mice, was also worsened in anti-GITR-treated animals. However, in contrast to what was observed in the BALB/c mouse strain \cite{1}, severe gastritis was not induced in NOD mice. In the autoimmune or inflammatory models cited above, the authors could not conclude whether the disease accelerating effect of GITR triggering was due to a decrease in the functional capacity of Tregs or to a stimulating/costimulatory effect on pathogenic T cells that also express GITR. We addressed
this important issue in the NOD mouse model. Of note are the higher proportions of CD4\(^+\) and CD8\(^+\) T cells showing an activated phenotype in anti-GITR-treated mice as compared to controls pointing, though indirectly, to an accelerated maturation/differentiation of peripheral T cells. Moreover, we collected evidence arguing for a major costimulatory effect on pathogenic/diabetogenic T cells of anti-GITR antibody contrasting with a lack of effect on Tregs.

First, in vitro, increasing concentrations of anti-GITR antibody exerted a costimulatory effect on the proliferative capacity and/or the IFN-\(\gamma\) production of CD4\(^+\)CD25\(^-\) T cells (depleted of Tregs) and CD8\(^+\) T cells in response to a polyclonal stimulation (i.e. anti-CD3). The same effect was observed in the context of an autoantigen-specific stimulation using CD4\(^+\) T cells from BDC2.5 NOD mice (that express an islet autoantigen-specific transgenic T cell receptor); a dose-dependent costimulatory effect was observed upon addition of anti-GITR as assessed by the IFN-\(\gamma\) production. Similarly, CD4\(^+\)CD25\(^-\) T cells recovered ex vivo from anti-GITR-treated mice exhibited a significantly enhanced proliferative capacity to suboptimal doses of anti-CD3. These findings fit with observations reported in models of EAE, asthma and collagen-induced arthritis showing enhanced CD4\(^+\) T cell activation, proliferation and cytokine production after administration of agonist anti-GITR antibodies [23,24].

Secondly, using an in vivo model in which CFSE-labeled pathogenic BDC2.5 NOD CD4\(^+\) T cells were transferred into young syngeneic recipients, we showed that, in anti-GITR-treated recipients, the migration of pathogenic effectors to the target tissue and its draining lymph nodes (i.e. within the infiltrated islets and pancreatic lymph nodes) as well as their in situ proliferation was greatly enhanced as compared to untreated control recipients. This phenomenon was accompanied by an enhanced CD8\(^+\) T cell migration within the islets of treated animals that may result from the combined effect of GITR triggering and the activating/chemoattracting factors produced by activated CD4\(^+\)BDC2.5 T cells.

Third, no effect of anti-GITR antibody on Treg function was found as assessed by a completely normal ability to suppress, in the conventional coculture system, of Tregs pre-treated in vitro with anti-GITR or recovered ex vivo from anti-GITR-treated NOD mice. These results confirm and extend previous results by McHugh et al. showing that GITR triggering on Tregs during a pre-activation phase (with anti-CD3 and IL-2) did not abrogate their suppressive capacity in a subsequent coculture assay with anti-CD3 or peptide-specific stimulated CD4\(^+\)CD25\(^-\) T cells [4]. In addition, in vivo, we were not able to detect in any lymphoid organ a significant increase in the number or proportion of Tregs at any time-point after administration of anti-GITR antibody although in vitro addition of anti-GITR increased Treg proliferation in response to CD3-specific antibody stimulation.

This lack of effect on regulatory CD4\(^+\)CD25\(^-\) T cells was reinforced by the fact that the disease accelerating effect of anti-GITR treatment could be obtained in the absence of thymus-derived natural Tregs that is the case of NOD mice deficient for CD28 (CD28\(^-/-\) NOD). These findings contrast with initial in vitro reports suggesting that ligation of GITR blocked the suppressive ability of freshly isolated Tregs [1,4]. This apparent contradiction may be interpreted in the light of more recent results by Stephens et al., using GITR\(^-/-\) mice, demonstrating that it is the engagement of GITR on effector T cells (but not on Tregs) which provides a co-activating signal rendering these cells resistant to regulation and as a consequence abrogating suppression [6]. Thus, in the autoimmune setting, GITR may influence the sensitivity of autoreactive T cells to stimulation by the cognate autoantigens, leading to an increased autoreactivity not properly controlled by Tregs. This possibility is further supported by data showing that GITR signaling lowers the threshold of T cell activation [47]. As a whole, our data suggest that the activation, proliferation and migration of effector T cells to the target tissue constitute the primary costimulatory effect of GITR triggering in vivo, overcoming the potential impact of anti-GITR on Tregs.

Now, coming to blockade of GITR signaling, the salient result is that it effectively protects from disease development. The original and interesting finding here is that significant protection was achieved even when anti-GITR antibody treatment started at 11 weeks of age i.e. a late pre-diabetic stage characterized by an already severe islet inflammation. Experiments are ongoing using higher cumulated dosages of anti-GITR antibody to improve the effect (i.e. complete protection from diabetes development). In addition, work is also in progress to test if GITR antibody therapy may also be effective at reversing recent onset established diabetes in NOD mice.

Interestingly, anti-GITR antibody treatment applied to the two in vivo models used to study effector T cells (i.e. CD28\(^-/-\) NOD mice and adoptive transfer of CFSE-labeled BDC2.5 T cells) gave opposite results as compared to anti-GITR agonist antibody treatment. Diabetes was significantly delayed yet not abolished in anti-GITR antibody-treated CD28\(^-/-\) NOD mice and BDC2.5 T cells showed reduced migration and proliferation in the islets and pancreatic lymph nodes of anti-GITR-treated recipient NOD mice as compared to untreated animals. As a mirror image with what found in the islets of anti-GITR-treated recipients, this reduced migration of CD4\(^+\) diabetogenic cells in anti-GITR antibody-treated mice correlated with a quite dramatic reduction in the proportion of infiltrating CD8\(^+\) T cells. Altogether, these results highlight that changes in antigen-specific CD4\(^+\) T cell migration and proliferation appear to significantly impact the recruitment of CD8\(^+\) effectors to the target tissue.

Two possibilities can explain that, although delayed, diabetes still occurred in anti-GITR antibody-treated CD28\(^-/-\) NOD mice. First, due to the absence of naturally occurring CD4\(^+\)CD25\(^-\) Tregs, these mice exhibited accelerated disease development when compared to wild-type NOD mice (i.e. a late pre-diabetic stage characterized by an already severe islet inflammation). Experiments are ongoing using higher cumulated dosages of anti-GITR antibody to improve the effect (i.e. complete protection from diabetes development). In addition, work is also in progress to test if GITR antibody therapy may also be effective at reversing recent onset established diabetes in NOD mice.

Interestingly, anti-GITR antibody treatment applied to the two in vivo models used to study effector T cells (i.e. CD28\(^-/-\) NOD mice and adoptive transfer of CFSE-labeled BDC2.5 T cells) gave opposite results as compared to anti-GITR agonist antibody treatment. Diabetes was significantly delayed yet not abolished in anti-GITR antibody-treated CD28\(^-/-\) NOD mice and BDC2.5 T cells showed reduced migration and proliferation in the islets and pancreatic lymph nodes of anti-GITR-treated recipient NOD mice as compared to untreated animals. As a mirror image with what found in the islets of anti-GITR-treated recipients, this reduced migration of CD4\(^+\) diabetogenic cells in anti-GITR antibody-treated mice correlated with a quite dramatic reduction in the proportion of infiltrating CD8\(^+\) T cells. Altogether, these results highlight that changes in antigen-specific CD4\(^+\) T cell migration and proliferation appear to significantly impact the recruitment of CD8\(^+\) effectors to the target tissue.

Two possibilities can explain that, although delayed, diabetes still occurred in anti-GITR antibody-treated CD28\(^-/-\) NOD mice. First, due to the absence of naturally occurring CD4\(^+\)CD25\(^-\) Tregs, these mice exhibited accelerated disease development when compared to wild-type NOD mice (i.e. a late pre-diabetic stage characterized by an already severe islet inflammation). Experiments are ongoing using higher cumulated dosages of anti-GITR antibody to improve the effect (i.e. complete protection from diabetes development). In addition, work is also in progress to test if GITR antibody therapy may also be effective at reversing recent onset established diabetes in NOD mice.
environment created by the insulin within pancreatic islets) enhance the homing potential of GITR-expressing autoreactive T cells.

From a more practical, clinically oriented perspective, these results point to the use of anti-GITRL as a novel avenue for the treatment of autoimmune type 1 diabetes. The incidence of autoimmune diabetes has tremendously increased in industrialized countries over the last three decades [49] and predictions for future years are alarming [44,45]. According to two recent reports, disease incidence has accelerated since 2000 and if present trends continue, the number of new cases diagnosed at or before 14 years of age will double in the next 15 years with onset at younger age (0–4 years) [44,45]. Therefore, establishing safe immune intervention strategies, that may provide a real cure for the disease, is both an urgent need and a real medical health challenge. Given the young age of the affected population, any candidate therapy must be safe and avoid a sustained depression of immune responses thus aiming at inducing or, in the case of established disease or to prevent it based on the use of candidate autoantigens or immune modulating drugs [50–53]. Although very encouraging, results so far are not totally satisfactory, and, as in many other clinical situations, one may predict that major improvements will be achieved as dosing schedules are adjusted and drug combinations are performed.

Our present data point to anti-GITRL antibodies as very good potential candidates whose capacity to block the migration to the target organ and the activation of pathogenic effectors appears fully complementary to that of other agents presently tested which preferentially target T cell-mediated regulatory pathways [51,53–59]. The question of whether an autoantigen-specific effect may be obtained is still open. One may speculate that although GITR is expressed on all T lymphocytes, blockade of GITR/ GITRL pathway may promote differential signaling depending on the nature and the functional capacity of T cell targets (i.e., a naive T cell, an activated or a memory T cell, a Treg), thus determining the ‘quality’ of the GITR antibody-mediated signal and the resulting outcome.

Acknowledgments

The authors are indebted to Fabrice Valette for managing the animal facility. They would also like to thank Jeffrey A. Bluestone for the gift of CD26+ NOD mice.

Author Contributions

Conceived and designed the experiments: SY. Performed the experiments: SY BS. Analyzed the data: SY JFB LC. Contributed reagents/materials/ analysis tools: LP SC CPL MR DR WHL HW. Wrote the paper: SY LC.

References

1. Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S (2002) Stimulation of CD25+/CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 3: 133–142.
2. Sakaguchi S (2005) Naturally arising Foxp3-expressing CD25(+)CD4(+) regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 6: 345–352.
3. Bluestone JA, Abbas AK (2003) Natural versus adaptive regulatory T cells. Nat Rev Immunol 3: 235–257.
4. McHugh RS, Whitters MJ, Pippiccola GA, Young DA, Slechav EM, et al. (2002) CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNFR receptor. Immunol 16: 311–323.
5. Tone M, Tone Y, Adams E, Yates SF, Frewin MR, et al. (2003) Mouse glucocorticoid-induced tumor necrosis factor receptor ligand is cistimulatory for T cells. Proc Natl Acad Sci U S A 100: 15059–15064.
6. Stephens GL, McHugh RS, Whitters MJ, Young DA, Lunenbery D, et al. (2004) Engagement of glucocorticoid-induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4+CD25(+)T cells. J Immunol 173: 5008–5020.
7. Kakamara F, Youngnak P, Hashiguchi M, Nishioka T, Takahashi T, et al. (2004) Cytosolic glucocorticoid-induced TNF receptor receptor in both conventional and CD25(+) regulatory CD4+ T cells. J Immunol 172: 7306–7313.
8. Ronghetti S, Zollo O, Bruscelli S, Agostini M, Bianchini R, et al. (2004) GITR, a member of the TNFR superfamily, is cistimulatory to mouse T lymphocyte subpopulations. Eur J Immunol 34: 613–622.
9. Ronchetti S, Necentinini G, Riccardi C, Pandolfi PP (2002) Role of GITR in activation response of T lymphocytes. Blood 100: 350–352.
10. Esparza EM, Arch RH (2005) Glucocorticoid-induced TNFR receptor, a cistimulatory receptor on naive and activated T cells, uses TNFR receptor-associated factor 2 in a novel fashion as an inhibitor of NF-kappa B activation. J Immunol 174: 7875–7882.
11. Esparza EM, Arch RH (2005) Glucocorticoid-induced TNFR receptor functions as a cistimulatory receptor that promotes survival in early phases of T cell activation. J Immunol 174: 7869–7874.
12. Kim JD, Choi BK, Bae JS, Lee UH, Han IS, et al. (2003) Cloning and characterization of GITR ligand. Genes Immun 4: 564–569.
13. Hanabuchi S, Watanabe N, Wang YH, Wang YH, Inoue T, et al. (2006) Human plasmacytoid dendritic cells activate NK cells through glucocorticoid-induced tumor necrosis factor receptor-ligand (GITR). J Immunol 174: 1089–1100.
14. Tayaerts S, Van Meirvenne S, Bonchill A, Heirman C, Corhals J, et al. (2007) Expression of human GITR on myeloid dendritic cells enhances their immunostimulatory function but does not abrogate the suppressive effect of CD4+CD25(+) regulatory T cells. J Leukoc Biol 82: 93–105.
15. Bae EM, Kim WJ, Suk K, Kang YM, Park JE, et al. (2007) Reverse signaling initiated from GITR induces NF-kappaB activation through ERK in the inflammatory activation of macrophages. Mol Immunol.

16. Shin HH, Lee MH, Kim SG, Lee YH, Kwon BS, et al. (2002) Recombinant glucocorticoid-induced tumor necrosis factor receptor (rGITR) induces NOS in 3T3-L1 adipocytes. FEBS Lett 514: 275–280.
17. Grohmann U, Volpi C, Pallarino F, Bozza B, Bianchi R, et al. (2007) Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy. Nat Med 13: 379–386.
18. Ko K, Yamazaki S, Nakamura K, Nishita T, Hirota K, et al. (2003) Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25(+) regulatory T cells. J Exp Med 202: 895–891.
19. Dittmer U, He H, Messer RJ, Schimmer S, Olbrich AR, et al. (2004) Functional impairment of CD4(+) T cells by regulatory T cells during persistent retroviral infection. Immunol 20: 295–303.
20. Cohen AD, Diab A, Perales MA, Wolbch JK, Rizzuto G, et al. (2006) Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. Cancer Res 66: 4904–4912.
21. Ramirez-Montagu T, Chow A, Hirschhom-Cymerman D, Tersewy TH, Kochman AA, et al. (2006) Glucocorticoid-induced TNFR receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigen antigens and enhances antitumor immunity. J Immunol 176: 6434–6442.
22. Piao J, Kamimura Y, Iwai H, Cao Y, Kikuchi K, et al. (2009) Enhancement of T-cell-mediated anti-tumour immunity via the ectopically expressed glucocorticoid-induced tumour necrosis factor receptor-related receptor ligand (GITRL) on tumours. Immunology 127: 489–499.
23. Kohan AP, Williams JS, Miller SD (2004) Cutting edge: ligation of the glucocorticoid-induced TNFR receptor enhances co-stimulatory CD4(+) T cell activation and experimental autoimmun e encephalomyelitis. J Immunol 172: 4066–4070.
24. Patel M, Xu D, Kevisn P, Cheow-Kang B, MacSharry C, et al. (2005) Glucocorticoid-induced TNFR family-related protein (GITR) activation exacerbates murine asthma and collagen-induced arthritis. Eur J Immunol 35: 3501–3590.
25. Cuzzocrea S, Ayroldi E, Di Paolo R, Agostini M, Mazzone E, et al. (2005) Role of glucocorticoid-induced TNFR family receptor gene (GITR) in collagen-induced arthritis. Faseb J 19: 1253–1265.
26. Cuzzocrea S, Ronchetti S, Genovese T, Mazzone E, Agostini M, et al. (2007) Genetic and pharmacological inhibition of GITR–GITRL interaction reduces chronic lung injury induced by bleomycin instillation. Faseb J 21: 117–129.
27. Santucci L, Agostini M, Brucelli S, Mucarello A, Ronchetti S, et al. (2007) GITR modulates innate and adaptive mucosal immunity during the development of experimental colitis in mice. Gut 56: 52–60.
28. Makino S, Kounimoto K, Muraka J, Mizushima Y, Katagiri K, et al. (1980) Genetic and pharmacological inhibition of GITR–GITRL interaction reduces chronic lung injury induced by bleomycin instillation. Faseb J 21: 117–129.
29. Katz JD, Wang B, Haskins K, Benoist C, Mathis D (1993) Following a diabetogenic T cell from genesis through pathogenesis. Cell 74: 1089–1100.
31. Cobbold SP, Castejon R, Adams E, Zelenika D, Graca L, et al. (2004) Induction of foxp3+ regulatory T cells in the periphery of T cell receptor transgenic mice tolerant to transplants. J Immunol 172: 6003–6010.

32. Bergman B, Haskins K (1994) Idiotypic-specific T-cell clones from the NOD mouse respond to beta-granule antigen. Diabetes 43: 197–203.

33. Haskins K, McPhiele M (1990) Acceleration of diabetes in young NOD mice with a CD4+ islet-specific T cell clone. Science 249: 1433–1436.

34. Peterson JD, Pike B, Dallas-pedretti A, Haskins K (1995) Induction of diabetes with idiotypic-specific T-cell clones is age dependent. Immunology 85: 453–460.

35. Hoglund P, Minter M, Watzinger C, Heath W, Beneist C, et al. (1999) Initiation of autoimmune diabetes by developmentally regulated presentation of islet antigens in the pancreatic lymph nodes. J Exp Med 189: 331–339.

36. Judkowski V, Pinilla C, Schrodle K, Tucker L, Nearnack N, et al. (2001) Identification of MHC class II-restricted peptide ligands, including a glutamic acid decarboxylase 65 sequence, that stimulate diabetogenic T cells from transgenic BDC2.5 nonobese diabetic mice. J Immunol 166: 908–917.

37. Ji HB, Liao G, Faubion WA, Alhadia-Molina AC, Cozzo C, et al. (2004) Cutting edge: the natural ligand for glucocorticoid-induced TNF receptor-related protein abrogates regulatory T-cell suppression. J Immunol 172: 5823–5827.

38. Lenczow DJ, Herold KC, Rhee L, Patel B, Kousu A, et al. (1996) CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes. Immunity 5: 283–293.

39. Salomon B, Lenczow DJ, Rhee L, Ashourian N, Singh B, et al. (2000) B7/CD28 Costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 12: 431–440.

40. Alyanakian MA, You S, Damotte D, Gouarin C, Esling A, et al. (2003) Diversity of regulatory CD4+ T cells controlling distinct organ-specific autoimmune diseases. Proc Natl Acad Sci U S A 100: 15890–15891.

41. Lepault F, Gagnerault MC (2000) Characterization of peripheral regulatory CD4+ T cells that prevent diabetes onset in nonobese diabetic mice. J Immunol 164: 249–257.

42. Peterson JD, Pike B, Dallas-pedretti A, Haskins K (1995) Induction of diabetes with idiotypic-specific T-cell clones is age dependent. Immunology 85: 453–460.

43. Bach JF (1994) Insulin-dependent diabetes mellitus as an autoimmune disease. Proc Natl Acad Sci U S A 100: 15806–15811.

44. Ronchetti S, Nocentini G, Bianchini R, Krausz LT, Migliorati G, et al. (2007) Glucocorticoid-induced TNFR-related protein lowers the threshold of CD28 costimulation in CD8+ T cells. J Immunol 179: 5916–5926.

45. Harjutsalo V, Jaresjo M, Hjorth M, Axelsson S, Cheramy M, et al. (2008) GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 359: 1909–1920.

46. Bodlender C, Hageopian W, Auger JA, Pousman Ruiz E, Taylor L, et al. (2002) Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 346: 1692–1698.

47. Skyler J (2002) Effects of insulin in relatives of patients with type 1 diabetes mellitus. Diabetes Prevention Trial-Type 1 Diabetes Study Group. N Engl J Med 346: 1685–1691.

48. You S, Belghith M, Cobbold S, Alyanakian MA, Gouarin C, et al. (2005) Autoimmune diabetes onset results from qualitative rather than quantitative age-dependent changes in pathogenic T-cells. Diabetes 54: 1413–1422.

49. Aylathan MA, You S, Damotte D, Gouarin C, Esling A, et al. (2003) Diversity of regulatory CD4+ T cells controlling distinct organ-specific autoimmune diseases. Proc Natl Acad Sci U S A 100: 15890–15891.

50. Lepault F, Gagnerault MC (2000) Characterization of peripheral regulatory CD4+ T cells that prevent diabetes onset in nonobese diabetic mice. J Immunol 164: 249–257.

51. Ludvigsson J, Faresjo M, Hjorth M, Axelsson S, Cheramy M, et al. (2008) GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 359: 1909–1920.

52. You S, Belghith M, Cobbold S, Alyanakian MA, Gouarin C, et al. (2005) Autoimmune diabetes onset results from qualitative rather than quantitative age-dependent changes in pathogenic T-cells. Diabetes 54: 1413–1422.

53. Keymeulen B, Vandeneulbroeke E, Ziegler AG, Mathieu C, Kaufman L, et al. (2005) Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 352: 2580–2608.

54. Tian J, Atkinson MA, Clare Salzler M, Herschfelder A, Forshuber T, et al. (1996) Nasal administration of glattamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J Exp Med 183: 1561–1567.

55. Halas B, Wang B, Sreeraze DV (1999) Induction of glutamic acid decarboxylase 65-specific Th2 cells and suppression of autoimmune diabetes at late stages of disease is epiphenomenal. J Immunol 163: 1178–1187.

56. Bot A, Smith D, Bot S, Hughes A, Wolf K, et al. (2003) Plasmid vaccination with insulin B chain prevents autoimmune diabetes in nonobese diabetic mice. J Immunol 167: 2950–2955.

57. Bagniul M, Stabilini A, Miehlevarca B, Horasjo-Horeck J, Kaugper T, et al. (2006) Kapanycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol 177: 8338–8347.

58. Belghith M, Bhoone JA, Barriot S, Megret J, Bach JE, et al. (2003) TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 9: 1202–1208.

59. Biukarska B, Colgan J, Laban J, Bhoone JA, Herold KC (2005) TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD4+CD25+ Tregs. J Clin Invest 115: 2904–2913.

60. Ronchetti S, Nocentini G, Bianchini R, Krausz LT, Migliorati G, et al. (2007) Glucocorticoid-induced TNFR-related protein lowers the threshold of CD28 costimulation in CD8+ T cells. J Immunol 179: 5916–5926.

61. Kamimura Y, Isai H, Piao J, Hashiguchi M, Azuma M (2009) The glucocorticoid-induced TNF receptor-related protein (GITR)-GITR ligand pathway acts as a mediator of cutaneous dendritic cell migration and promotes T cell-mediated acquired immunity. J Immunol 182: 2708–2716.

62. Bach JF (2002) The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 347: 911–920.

63. Skyler J (2002) Effects of insulin in relatives of patients with type 1 diabetes mellitus. Diabetes Prevention Trial-Type 1 Diabetes Study Group. N Engl J Med 346: 1685–1691.

64. Ludwigsson J, Faresjo M, Hjorth M, Axelsson S, Cheramy M, et al. (2008) GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 359: 1909–1920.

65. Herold KC, Hageopian W, Auger JA, Pousman Ruiz E, Taylor L, et al. (2002) Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 346: 1692–1698.